Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (121)
  2. Journal Article (92)
  3. Review (7)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
  7. Research Letter (1)
Groups
  1. Breast Medicine Service (225)
  2. Department of Medicine (225)
  3. Solid Tumor Oncology Division (225)
  4. GSK Faculty (59)
  5. Survivorship Research (48)
  6. Hematology-Oncology Fellows (46)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (29)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (31)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (11)
  5. New England Journal of Medicine (6)
  6. European Journal of Cancer (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (49)
  3. Oxford University Press (23)
  4. Elsevier Inc. (17)
  5. Springer (7)
  6. Massachusetts Medical Society (6)

More Publishers

Results (225)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor ER protein modulation, molecular characterization and monitoring of cfDNA in phase 1 study of LSZ102 and LSZ102 + ribociclib in patients with ER+ MBC
    Meeting Abstract

    Jhaveri, K.; Juric, D.; Cresta, S.; Yap, Y. S.; Duhoux, F. P.; Terret, C.; Layman, R.; Balbin, A.; Sheng, Q.; Liao, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)
    Meeting Abstract

    Jhaveri, K.; Juric, D.; Cresta, S.; Yap, Y. S.; Duhoux, F. P.; Terret, C.; Layman, R.; Kundamal, N.; Liao, S.; Ji, Y.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer
    Meeting Abstract

    Jhaveri, K.; Kalinsky, K.; Bedard, P.; Cervantes, A.; Saura, C.; Krop, I.; Hamilton, E.; Schmid, P.; Varga, A.; Turner, N.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER(+)) HER2-negative (HER2(-)) metastatic breast cancer
    Meeting Abstract

    Jhaveri, K.; Winer, E. P.; Lim, E.; Fidalgo, J. A. P.; Bellet, M.; Mayer, I. A.; Boni, V.; Patel, J. M.; Bardia, A.; Garcia, J. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Real-world predictors of first-line treatment and descriptive outcomes in HR(+)/HER2(-) metastatic breast cancer patients in the US
    Meeting Abstract

    Downer, M. K.; Jhaveri, K.; Bardia, A.; Loi, S.; Kent, M.; Luhn, P.; Humke, E. W.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Genomic profiling of primary and metastatic breast cancer in men
    Meeting Abstract

    Drago, J. Z.; Serna-Tamayo, C.; Dos Anjos, C. H.; Brown, D. N.; Modi, S.; Jhaveri, K.; Solit, D. B.; Traina, T. A.; Chandarlapaty, S.; Reis-Filho, J. S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • ER pathway activity signature as a biomarker for endocrine agent GDC-9545
    Meeting Abstract

    Daemen, A.; Spoerke, J. M.; Zhou, W.; Guan, J.; Ingalla, E.; Young, A.; Hafner, M.; Aimi, J.; Chang, C. W.; Giltnane, J. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)
    Meeting Abstract

    Jhaveri, K.; Juric, D.; Yap, Y. S.; Cresta, S.; Layman, R.; Duhoux, F.; Terret, C.; De Vita, S.; Kundamal, N.; He, W.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
    Journal Article

    Xu, G.; Chhangawala, S.; Cocco, E.; Razavi, P.; Cai, Y.; Otto, J. E.; Ferrando, L.; Selenica, P.; Ladewig, E.; Chan, C.; more...
    Nature Genetics (2020)

    Fulltext@MSK | Save
  • Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer
    Journal Article

    Smyth, L. M.; Piha-Paul, S. A.; Won, H. H.; Schram, A. M.; Saura, C.; Loi, S.; Lu, J.; Shapiro, G. I.; Juric, D.; Mayer, I. A.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save